Over the past five years, the cosmetic industry has met with several legislative changes. Within the new legislative package, including the new REACH and CLP, it is important to find a comfortable routine that will minimize costs while staying effective and compliant with all regulations.
Quality Assurance Practices in Pharmaceutical Manufacturing to Be Discussed in Moscow
Russian and foreign pharmaceutical companies are gathering in Moscow for the 2nd annual “Quality Assurance in Pharma Manufacturing, Russia and EAEU” conference, organized by Fleming.
The conference's program presents the key aspects of quality assurance: innovative approaches and trends in quality for safety and efficiency assurance; localization; validation and risk management; optimization at the manufacturing site; and creating an effective personnel training system.
The issues being touched upon in the course of the conference are significant for pharmaceutical companies in Russia and in other EAEU countries: Kazakhstan, Armenia, Kyrgyzstan and Belarus. On top of that, guest speakers from European countries will take part in the conference to share their ideas in quality assurance.
Participants will have a chance to meet with Akrikhin, Sanofi, Teva, Bayer, Berlin-Pharma and Petrovax-Pharm representatives, as well as with experts from leading associations to obtain up-to-date information for creating efficient production processes and enhancing the quality of medicines.
The format of working sessions ensures efficient knowledge transfer for all participants, owing to panel discussions, interactive presentations, case studies and “world café” debates taking place during the conference.
The “Quality Assurance in Pharma Manufacturing, Russia and EAEU” conference is officially supported by the Association of International Pharmaceutical Manufacturers (AIPM), the Association of Russian Pharmaceutical Manufacturers (ARPM), the Union of Professional Pharmaceutical Associations (UPPA) and the Pharmaceutical Innovations Association.
Find out more about the event at:
Interested in this topic?
Advanced Protein Aggregation & Characterization
This training will focus on occurrence of particles in drug products, effects of protein aggregates, critical process and parameters. Attendees will gain overview of on utility and limits of predictive experiments, learn concerns from the authorities and relevant aggregation guidelines, and more.
CMC Analytical Comparability: Methods & Strategies for Biologics, Biosimilars & Biobetters
Attendees will be introduced to comparability in biosimilar development, the analytical strategies of protein characterization of biosimilars, the structure of proteins, in vitro pharmacology and much more.
Corporate Compliance & Transparency in the Pharmaceutical Industry
This two-day conference will serve as a platform for an open and dynamic dialogue with HCPs and patients to achieve common goals. Learn how to embed compliance in the business and develop one simple system for managing compliance & transparency in a complex and regulated environment.
Driving the national agenda of Medical tourism through PX Excellence
Read the interview with Dr. Layla Al-Marzouqi, Director of Medical Tourism Council at Dubai Health Authority, and learn how to enrich patient experience and quality of healthcare.
No more trouble with dangerous good shipments
Global temperature controlled pharmaceutical shipments are constantly faced with new logistics challenges and regulations. This January 2017, IATA Dangerous Goods Regulations added further complexity to shipping cold chain products compliantly.
5 Changes in Signal Detection Management
The European Medicines Agency, regulatory authorities in the Member States and marketing authorisation holders are responsible for detecting and managing safety signals. A safety signal is generally defined as information about a new or known Adverse Event that may have been caused by a medicine, where it is therefore necessary to conduct further investigation. Evaluation of safety signals plays a major role within pharmacovigilance. Therefore, it is vital for regulatory authorities to know the latest updates detailing the risks and benefits of medicines. The EudraVigilance database is an important source of information on suspected adverse reactions and signals.